๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hematological Malignancies
Clinical trial register · China

Hematological Malignancies Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 9 Hangzhou 7 Tianjin 4 Beijing 3 Xi'an 3
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou9 Hangzhou7 Tianjin4 Beijing3 Xi'an3
All 19 locations
Target enrolment
to

Hematological Malignancies trials in China

18 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies
NCT07809139Hematological Malignancies
DrugCHT101
Nanjing Miracle Biotechnology Co., Ltd.
Phase 1
30
Nanchang
2026-09
Not yet open
mNGS for IFD in Patients With Hematological Malignancies
NCT07763184Hematological Malignancies, Invasive Fungal Disease
Nanfang Hospital, Southern Medical University
Observational
50
Guangzhou
2026-08-10
Not yet open
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies
NCT07636486Luspatercept, Epoetin, Poor Erythroid Engraftment, Hematological Malignancies
Nanfang Hospital, Southern Medical University
Phase 2/3
90
Guangzhou
2026-06-15
Not yet open
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
NCT07539779Luspatercept, Poor Erythroid Engraftment, Hematological Malignancies, Myelofibrosis (MF)
Nanfang Hospital, Southern Medical University
Phase 2/3
196
Guangzhou
2026-05-01
Not yet open
Prospective Study Evaluate the Timing of Empirical Treatment for Carbapenem-resistant Bacterials (CROEAT Study)
NCT07047352Carbapenem-resistant Enterobacterales, Neutropenia, Hematological Malignancies
Shanghai Jiao Tong University School of Medicine
Not applicable
91
Shanghai
2025-08-01
Recruiting
18F-Pentixafor PET in Hematologic Malignancies
NCT07122674Hematological Malignancies
First Affiliated Hospital of Zhejiang University
Observational
100
Hangzhou
2025-07-01
Recruiting
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
NCT06387082Hematological Malignancies
Hutchmed
Phase 1
132
Changsha, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan
2024-05-27
Recruiting
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
NCT06224855Advanced Solid Tumors, Hematological Malignancies
DrugDXC006
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
280
Hefei, Guangzhou, Changsha, Nanchang, Hangzhou
2024-01-24
Recruiting
The Study of ICP-248 in Patients With Mature B-cell Malignancies
NCT05728658Hematological Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
191
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhengzhou
2023-03-09
Recruiting
Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology
NCT05306509Solid Tumor, Hematological Malignancies
Children's Hospital of Fudan University
Not applicable
120
Shanghai
2022-08-01
Active, closed
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
NCT05347225Hematological Malignancies
Merck Sharp & Dohme LLC
Phase 1
12
Guangzhou, Zhengzhou, Changsha, Tianjin
2022-06-09
Recruiting
A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging
NCT06834412Hematological Malignancies
Xijing Hospital
Not applicable
120
Xi'an
2021-11-03
Recruiting
National Longitudinal Cohort of Hematological Diseases (NICHE) - CART
NCT06607289Hematological Malignancies
Institute of Hematology & Blood Diseases Hospital, China
Observational
1,000
Tianjin
2021-06-01
Recruiting
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552Hematological Malignancies
Janssen Research & Development, LLC
Phase 2
510
Beijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Xi'an
2021-02-01
Not yet open
LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies
NCT04657965Infectious Diseases, Hematological Malignancies
Zhejiang University
Phase EARLY_PHASE1
144
Hangzhou
2021-01-15
Not yet open
Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies
NCT04662788Hematological Malignancies
Zhejiang University
Phase EARLY_PHASE1
36
Hangzhou
2021-01-01
Active, closed
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557098Hematological Malignancies
Janssen Research & Development, LLC
Phase 2
194
Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Xi'an
2020-09-17
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/hematological-malignancies

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies listing the condition Hematological Malignancies.

How many Hematological Malignancies trials are recruiting in China?

8 of the 18 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 8 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hematological Malignancies), 18 studies
PhaseStudiesRecruitingShare
Phase 16333.3%
Not applicable3216.7%
Observational3216.7%
Phase 22111.1%
Phase 2/32011.1%
Phase EARLY_PHASE12011.1%

Most active sponsors

Lead sponsors with the most studies (Hematological Malignancies)
Lead sponsorStudiesRecruiting
Nanfang Hospital, Southern Medical University30
Janssen Research & Development, LLC21
Nanjing Miracle Biotechnology Co., Ltd.20
Zhejiang University20
Beijing InnoCare Pharma Tech Co., Ltd.11
Children's Hospital of Fudan University11
First Affiliated Hospital of Zhejiang University11
Hangzhou DAC Biotechnology Co., Ltd.11
Hutchmed11
Institute of Hematology & Blood Diseases Hospital, China11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.